Cardiovascular Disease Archives - Page 98 of 102 - Clinical Advisor

Cardiovascular Disease

Switch cholesterol therapy?

I have a patient with severe coronary artery disease (he has already had quadruple bypass) and multiple risk factors for metabolic syndrome. His LDL goal is being met with ezetimibe 10 mg/simvastatin 80 mg (Vytorin 10/80). Given the results of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial showing that Vytorin lowers…

Rosuvastatin lowers mortality and cardiovascular events in patients with high CRP, normal cholesterol

Level 1: Likely reliable evidenceThe Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) studied the use of rosuvastatin (Crestor) for prevention of cardiovascular events in patients with normal cholesterol levels but elevated C-reactive protein (CRP) levels (N Engl J Med. 2008;359:2195-2207). A total of 17,802 patients (11,001 men…

CRP vs. LDL as a stroke predictor

In my practice, C-reactive protein (CRP) appears to be better than LDL at predicting such ischemic events as infarcts or strokes. Among my patients at high risk for ischemic events, those treated with rosuvastatin and simvastatin seem to do better than those taking other statins. (Those taking the ACE inhibitor ramipril also do well, but…

Fibrate used in combination with statin approved

The FDA has approved Trilipix (fenofibric acid), a delayed-release capsule for use along with diet to treat dyslipidemia. Trilipix is the first fibrate to be approved for use in combination with a statin.

Top 10 health stories of 2008

Blood sugar goals, stem cells, CT scans, health reform–these are some of the issues to make the list of most important stories of the year, as chosen by the Harvard Health Letter.

Statins protect against CVD, not renal disease

Statin use does not decrease renal-function loss in patients without cardiovascular disease (CVD) or in those at risk for it, but the drug is effective for primary prevention of CVD, a study found.

Next post in News